Investors

Welcome to the PHAXIAM Therapeutics investor area

Corporate profile

PHAXIAM is a clinical-stage biopharmaceutical company developing innovative bacteriophage-based therapies to fight antimicrobial resistance (AMR).

INNOVATIVE APPROACH

PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.

PHAGES PORTFOLIO

PHAXIAM développe un portefeuille de phages ciblant 3 des bactéries les plus résistantes et les plus dangereuses, qui représentent à elles seules plus des deux tiers des infections nosocomiales résistantes : Staphylococcus aureus, Escherichia coli et Pseudomonas aeruginosa .

DUAL LISTING

PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

STOCK QUOTE

Corporate presentation

231011 PHAXIAM_presentation_Page_01
231011 PHAXIAM_presentation_Page_02
231011 PHAXIAM_presentation_Page_03
231011 PHAXIAM_presentation_Page_04
231011 PHAXIAM_presentation_Page_05
231011 PHAXIAM_presentation_Page_06
231011 PHAXIAM_presentation_Page_07
231011 PHAXIAM_presentation_Page_08
231011 PHAXIAM_presentation_Page_09
231011 PHAXIAM_presentation_Page_10
231011 PHAXIAM_presentation_Page_11
231011 PHAXIAM_presentation_Page_12
231011 PHAXIAM_presentation_Page_13
231011 PHAXIAM_presentation_Page_14
231011 PHAXIAM_presentation_Page_15
231011 PHAXIAM_presentation_Page_16
231011 PHAXIAM_presentation_Page_17
231011 PHAXIAM_presentation_Page_18
231011 PHAXIAM_presentation_Page_19
231011 PHAXIAM_presentation_Page_20
231011 PHAXIAM_presentation_Page_21
231011 PHAXIAM_presentation_Page_22
previous arrow
next arrow
231011 PHAXIAM_presentation_Page_01
231011 PHAXIAM_presentation_Page_02
231011 PHAXIAM_presentation_Page_03
231011 PHAXIAM_presentation_Page_04
231011 PHAXIAM_presentation_Page_05
231011 PHAXIAM_presentation_Page_06
231011 PHAXIAM_presentation_Page_07
231011 PHAXIAM_presentation_Page_08
231011 PHAXIAM_presentation_Page_09
231011 PHAXIAM_presentation_Page_10
231011 PHAXIAM_presentation_Page_11
231011 PHAXIAM_presentation_Page_12
231011 PHAXIAM_presentation_Page_13
231011 PHAXIAM_presentation_Page_14
231011 PHAXIAM_presentation_Page_15
231011 PHAXIAM_presentation_Page_16
231011 PHAXIAM_presentation_Page_17
231011 PHAXIAM_presentation_Page_18
231011 PHAXIAM_presentation_Page_19
231011 PHAXIAM_presentation_Page_20
231011 PHAXIAM_presentation_Page_21
231011 PHAXIAM_presentation_Page_22
previous arrow
next arrow
   

Latest press releases

Upcoming events

November 28, 2023

Investir Day - Paris - Carrousel du Louvre - https://www.investirday.fr/

December 05, 2023

Geneva MidCap Event - Royal Hotel - Participants: Thibaut du Fayet, Eric Soyer https://geneva2023.cfbcom.com/

Audit Committee

PHAXIAM’s Audit Committee assists our board of directors in its oversight of our corporate accounting and financial reporting and submits the selection of our statutory auditors, their remuneration and independence for approval. It is composed of Hilde Windels, Philippe Archinard and Eric Leire for the Board of Directors and Eric Soyer and Thibaut du Fayet who represent PHAXIAM’s management team.

Clinical Strategy Committee

Our clinical strategy committee is responsible for analyzing and reviewing our clinical and regulatory strategy. It meets, at least once a year, and makes recommendations to PHAXIAM’s Board of Directors regarding our clinical and regulatory development strategy.

PHAXIAM’s clinical strategy committee is composed of Martine George, Philippe Archinard and Robert Sebbag for the Board of Directors and Pascal Birman, Frédérique Vieville and Thibaut du Fayet who represent PHAXIAM’s management team.

 

Remuneration and appointments committee

The Remuneration and Appointments Committee hears the directors’ assessments of PHAXIAM’s performance against defined objectives. It meets at least once a year, without the directors being present, to assess their individual performance and, after conferring with them, makes recommendations to the Board of Directors concerning their remuneration.

It is composed of Philippe Archinard, Leïla Nicolas et Hilde Windels for the Board of Directors, and Eric Soyer, Chief Financiel Officer, Chief Operating Officer and Deputy General Manager of PHAXIAM.

Bylaws, internal rules and miscellaneous

Press releases

Past press releases

Financial calendar and upcoming events

November 28, 2023

Investir Day - Paris - Carrousel du Louvre - https://www.investirday.fr/

December 05, 2023

Geneva MidCap Event - Royal Hotel - Participants: Thibaut du Fayet, Eric Soyer https://geneva2023.cfbcom.com/

Past webcasts

download

HYR 2023 presentation [PDF]

download

ERYTECH – Webcast of Thursday, February 16, 2023 on the proposed merger between Erytech and Pherecydes [PDF]

download

ERYTECH – Webconference Tuesday November 22, 2022: Q3 2022 quarterly results [PDF]

download

ERYTECH – Webconference Tuesday, September 13, 2022: Q2 and H1 2022 results [PDF]

download

ERYTECH – Webconference on Monday, March 14, 2022: Q4 and full-year results 2021 [PDF]

download

ERYTECH – Webconference Tuesday November 16, 2021: Q3 2021 quarterly results [PDF]

download

ERYTECH – Webconference September 21, 2021: H1 2021 results [PDF]

download

ERYTECH – Webconference May 5, 2021: Quarterly results Q1 2021 [PDF]

download

ERYTECH – Webconference March 9, 2021: full-year results 2020 [PDF]

download

PHERECYDES – January 21, 2021: Investor Presentation - IPO [PDF]

download

ERYTECH – Webconference November 6, 2020: Q3 2020 quarterly results [PDF]

download

ERYTECH – Webconference September 22, 2020: H1 2020 results [PDF]

download

ERYTECH – Webconference May 7, 2020: Q1 2020 quarterly results [PDF]

download

ERYTECH – Webconference March 17, 2020: full-year results 2019 [PDF]

Universal Registration Document

Financial reports

Financial reports

Quarterly Financial Information

Periodical information

Total Numbers of Voting Rights and Shares

Other documents

Equity offerings

Dépôts SEC

Shareholders Meetings

Stock quote

Historical price

Analyst coverage

Company
Analysts
Latest analyst note
Portzamparc
Mohamed Kaabouni
TP ICAP Midcap
Claire Deray

Please note that any opinions, estimates or forecasts regarding ERYTECH Pharma performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ERYTECH Pharma or its management. ERYTECH Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

Investor alerts

Would you like to subscribe to our alerts to receive all our investor information directly in your mailbox? Please enter your email address in the field below and select the type of information you are interested in.

We respect your privacy and will not share your data with third parties. You can unsubscribe at any time from alerts to which you have subscribed.

For more information on our data protection policy, please consult our privacy policy.

INVESTORS CONTACT

To contact our investor relations team

PHAXIAM

Eric Soyer
CFO, COO and Deputy General Manager
+33(0)4 78 74 44 38
investors@phaxiam.com

Investor relations
NewCap

Mathilde Bohin / Dusan Oresansky
+33(0)1 44 71 94 94
phaxiam@newcap.eu

Media relations
NewCap

Arthur Rouillé
+33(0)1 44 71 94 94
phaxiam@newcap.eu

Contact
our team

Journalist, investor, healthcare professional, partner or candidate... if you have any questions about PHAXIAM, please do not hesitate to contact our teams.

Contact us